Trending News

Lungs
#Boehringer Ingelheim #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase I trial

Over 60% response in lung cancer tumours with rare mutation

Boehringer Ingelheim has reported positive results from its Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 trial evaluating zongertinib (BI 1810631) in pre-treated patients with advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations. Zongertinib, an investigational oral HER2 tyrosine kinase inhibitor… Read More

#Cancer Research #News #Trending News

Ozempic (semaglutide)
#Cardiovascular disease #Covid-19 #Diabetes #GLP-1 #Weight loss

Semaglutide reduces risk of all-cause death

Semaglutide has been found to reduce the rates of all-cause death, including as a result of Covid-19, in those who are overweight or have obesity and established cardiovascular disease without diabetes. The findings were published in JACC, the journal of the American College… Read More

#News #Trending News

Lecanemab
#Alzheimer's #Eisai #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #UK

UK regulator rules benefits of lecanemab do not justify the cost

The benefits of Alzheimer’s drug lecanemab (Leqembi) are too small to justify the cost of providing the treatment to NHS patients, the UK regulator has ruled. This was the decision by the National Institute for Health and Care Excellence (NICE) in draft guidance on the drug. Lecanemab is for slowing… Read More

#News #Regulatory #Trending News

Human heart
#Cardiovascular disease #GLP-1 #Heart failure #Obesity #University College London #Weight loss

Semaglutide could also benefit patients with heart failure

A new study indicates that anti-obesity drug semaglutide helps prevent cardiac events among overweight people who have cardiovascular disease, even if they also have heart failure. The results follow a previous finding that weekly injections of semaglutide were linked to a 20% reduction in major adverse cardiac events (MACE) such… Read More

#News #Trending News

Patient injects Ozempic
#Adverse event #Diabetes #GLP-1 #Obesity #Weight loss

Semaglutide found to increase risk of suicidal thoughts

A new study has suggested a link between semaglutide (the active ingredient in Wegovy and Ozempic) and a disproportionately increased reporting of suicidality. Semaglutide has recently been treated as something of a wonder drug, with studies demonstrating it can reduce the risk of cardiovascular disease,… Read More

#News #Trending News

Endometrial biopsy
#AstraZeneca #European Commission #Immunotherapy #Oncology #PARP inhibitors #Phase III trial

Lynparza and Imfinzi combination approved in the EU for endometrial cancer

AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union (EU) as treatment for certain patients with primary advanced or recurrent endometrial cancer. Imfinzi plus chemotherapy as first-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch repair proficient (pMMR) disease. Imfinzi plus… Read More

#News #Regulatory #Trending News

Soft tissue sarcoma
#Adaptimmune Therapeutics #Cell therapy #FDA #Oncology #Solid tumours

First engineered cell therapy for a solid tumour gets US approval

Adaptimmune Therapeutics’ Tecelra (afamitresgene autoleucel) has become the first engineered cell therapy for a solid tumour cancer approved in the US. It is also the first new therapy option in more than a decade for synovial sarcoma, which is a rare, soft tissue cancer that most commonly impacts young adults. Read More

#News #Regulatory #Trending News

Jigsaw puzzle of the brain
#Alzheimer's #Dementia #Diabetes #GLP-1 #Novo Nordisk #Phase II trial #Weight loss

GLP-1 receptor agonist slows Alzheimer’s cognitive decline

In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia. In a Phase IIb trial, Novo Nordisk’s GLP-1 receptor agonist liraglutide appears to reduce shrinking in the parts of the brain that control memory, learning, language… Read More

#News #Trending News

Smoking cessation
#Addiction #Case Western Reserve University School of Medicine #Diabetes #GLP-1 #Nicotine addiction #Smoking cessation #Weight loss

Semaglutide (Ozempic) found to treat smoking addiction

New research has linked semaglutide (the active ingredient in Wegovy and Ozempic) with improved smoking cessation. Rong Xu and colleagues at the Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, US, have reported a reduced desire to smoke in patients… Read More

#News #Trending News

Stamp of approval
#CHMP #EMA #European Medicines Agency #European Union #Marketing approval authorisation

EU’s CHMP supports 14 new medicines, but rejects lecanemab

The European Medicine Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended 14 medicines for approval at its July 2024 meeting. However, the CHMP recommended not granting a marketing authorisation for Leqembi (lecanemab) for the treatment of Alzheimer’s disease. The committee said that the observed effect of Leqembi… Read More

#News #Regulatory #Trending News

Cancer cell
#Breast Cancer Now #Oncology #The Institute of Cancer Research #Treatment resistance

Science reveals how cancer cells outsmart normal cells

Scientists have discovered that some cancer cells pretend to be ‘super fit’ to fool normal healthy cells into giving them their nutrients, allowing them to expand and spread around the body. A team from The Institute of Cancer Research (ICR), London, found that ‘cheating’ cancer cells… Read More

#Cancer Research #News #Trending News

UK visa application
#Cancer Research UK #Life sciences #Politics #UK #UK government

Strict UK immigration rules hold back cancer research

The UK immigration system is making it much harder for the country’s research institutions to compete for international talent, says Cancer Research UK (CRUK). With their annual visa costs projected to rise by 44% in a single year, the organisation is calling on the new UK… Read More

#News #Trending News

Liver cancer
#Colorectal cancer #ETH Zurich #Liver cancer #Oncology #Tumour microenvironment (TME)

Study reveals how cancer cells metastasise to the liver

Researchers at ETH Zurich in Switzerland have uncovered how colorectal cancer cells colonise the liver. The findings, by Andreas Moor in the Department of Biosystems Science and Engineering and his team, will help to develop treatments with which they hope could hinder the metastatic process. Read More

#Cancer Research #News #Trending News

Cancer cells
#Cancer drug targets #Genetics / genomics #Institute of Cancer Research #Oncology #University of Cambridge #Wellcome Sanger Institute

Researchers identify potential new genetic target for cancer drugs

UK researchers have mapped the exact variants in a gene that dramatically increase a person’s risk of developing cancer, paving the way for targeted treatment across diverse populations. Over 5,000 genetic variants that enable certain cancers to thrive were identified, along with a potential therapeutic target… Read More

#Cancer Research #News #Trending News

Ageing hands
#Age-related diseases (ARDs) #Ageing #Peptides #University of Birmingham

Natural peptide could protect against ‘inflammageing’

A naturally occurring peptide called ‘peptide inhibitor of trans-endothelial migration’ (PEPITEM) could potentially rejuvenate the immune response in older individuals, according to a new study. The authors believe the peptide could protect against ‘inflammageing’, widely believed to be the root cause of many age-related diseases. Read More

#News #Trending News

Patient on ventilator
#Covid-19 #Covid-19 treatment #Drug repurposing #Francis Crick Institute #Pneumonia #University College London

Repurposed drug treats severe Covid-19 pneumonia

A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe Covid-19 pneumonia in a recent clinical trial. The drug, dornase alfa, could be used to treat other respiratory infections, according to the data from researchers at UCL, UCLH and the Francis Crick… Read More

#News #Trending News